Methods of treatment using CTLA-4 antibodies

Details Methods of treatment using CTLA-4 antibodies Methods of treatment using CTLA-4 antibodies

2003-04-11

2008-11-18

Ouspenski, Ilia (Department: 1644)

Drug, bio-affecting and body treating compositions

Immunoglobulin, antiserum, antibody, or antibody fragment,...

C424S133100, C424S142100, C424S143100, C424S154100, C530S387100, C530S387300, C530S388150, C530S388220, C530S388750

Reexamination Certificate

active

07452535

ABSTRACT:
The present invention provides method of treatment using human sequence antibodies against human CTLA-4. In particular, methods of treating cancer are provided.

REFERENCES:
patent: 4399216 (1983-08-01), Axel et al.
patent: 4681581 (1987-07-01), Coates
patent: 4683195 (1987-07-01), Mullis et al.
patent: 4683202 (1987-07-01), Mullis
patent: 4735210 (1988-04-01), Goldenberg
patent: 4740461 (1988-04-01), Kaufman
patent: 4816397 (1989-03-01), Boss et al.
patent: 4921040 (1990-05-01), Ueruenduel et al.
patent: 4959455 (1990-09-01), Clark et al.
patent: 5101827 (1992-04-01), Goldenberg
patent: 5151510 (1992-09-01), Stec et al.
patent: 5194594 (1993-03-01), Khawli et al.
patent: 5434131 (1995-07-01), Linsley et al.
patent: 5530101 (1996-06-01), Queen et al.
patent: 5545806 (1996-08-01), Lonberg et al.
patent: 5545807 (1996-08-01), Surani et al.
patent: 5569825 (1996-10-01), Lonberg et al.
patent: 5585089 (1996-12-01), Queen et al.
patent: 5591669 (1997-01-01), Krimpenfort et al.
patent: 5612205 (1997-03-01), Kay et al.
patent: 5625126 (1997-04-01), Lonberg et al.
patent: RE35500 (1997-05-01), Rhodes
patent: 5633425 (1997-05-01), Lonberg et al.
patent: 5643763 (1997-07-01), Dunn et al.
patent: 5648471 (1997-07-01), Buttram et al.
patent: 5661016 (1997-08-01), Lonberg et al.
patent: 5693761 (1997-12-01), Queen et al.
patent: 5693792 (1997-12-01), Torii et al.
patent: 5697902 (1997-12-01), Goldenberg
patent: 5703057 (1997-12-01), Johnston et al.
patent: 5714350 (1998-02-01), Co et al.
patent: 5721367 (1998-02-01), Kay et al.
patent: 5733743 (1998-03-01), Johnson et al.
patent: 5741957 (1998-04-01), Deboer et al.
patent: 5750172 (1998-05-01), Meade et al.
patent: 5756687 (1998-05-01), Denman et al.
patent: 5770197 (1998-06-01), Linsley et al.
patent: 5770429 (1998-06-01), Lonberg et al.
patent: 5773253 (1998-06-01), Linsley et al.
patent: 5777085 (1998-07-01), Co et al.
patent: 5789215 (1998-08-01), Berns et al.
patent: 5789650 (1998-08-01), Lonberg et al.
patent: 5811097 (1998-09-01), Allison et al.
patent: 5814318 (1998-09-01), Lonberg et al.
patent: 5844095 (1998-12-01), Linsley et al.
patent: 5855887 (1999-01-01), Allison et al.
patent: 5874299 (1999-02-01), Lonberg et al.
patent: 5877397 (1999-03-01), Lonberg et al.
patent: 5885796 (1999-03-01), Linsley et al.
patent: 5916771 (1999-06-01), Hori et al.
patent: 5939598 (1999-08-01), Kucherlapati et al.
patent: 5968510 (1999-10-01), Linsley et al.
patent: 5977318 (1999-11-01), Linsley et al.
patent: 6051227 (2000-04-01), Allison et al.
patent: 6075181 (2000-06-01), Kuckerlapati et al.
patent: 6114598 (2000-09-01), Kuckerlapati et al.
patent: 6150584 (2000-11-01), Kuckerlapati et al.
patent: 6162963 (2000-12-01), Kuckerlapati et al.
patent: 6207156 (2001-03-01), Kuchroo et al.
patent: 6255458 (2001-07-01), Lonberg
patent: 6682736 (2004-01-01), Hanson et al.
patent: 6719972 (2004-04-01), Gribben et al.
patent: 2001/0036458 (2001-11-01), Hiserodt et al.
patent: 2002/0039581 (2002-04-01), Carreno et al.
patent: 2002/0086014 (2002-07-01), Korman et al.
patent: 2002/0182218 (2002-12-01), Nicolette
patent: 2003/0086930 (2003-05-01), Mueller et al.
patent: 2003/0175250 (2003-09-01), Jager et al.
patent: 2205680 (1998-11-01), None
patent: 0 216 846 (1987-04-01), None
patent: 0 256 055 (1988-02-01), None
patent: 0 323 997 (1989-07-01), None
patent: 0 338 841 (1989-10-01), None
patent: 0 463 151 (1992-01-01), None
patent: 0 546 073 (1993-06-01), None
patent: 1 262 193 (2002-12-01), None
patent: WO 91/10741 (1991-07-01), None
patent: WO 92/03918 (1992-03-01), None
patent: WO 92/22645 (1992-12-01), None
patent: WO-92/22647 (1992-12-01), None
patent: WO-92/22670 (1992-12-01), None
patent: WO-93/00431 (1993-01-01), None
patent: WO 93/12227 (1993-06-01), None
patent: WO-00/00569 (1994-01-01), None
patent: WO 94/02602 (1994-02-01), None
patent: WO 94/25585 (1994-11-01), None
patent: WO-94/29444 (1994-12-01), None
patent: WO-95/01994 (1995-01-01), None
patent: WO-95/03408 (1995-02-01), None
patent: WO-95/24217 (1995-09-01), None
patent: WO 95/33770 (1995-12-01), None
patent: WO-96/14436 (1996-05-01), None
patent: WO-96/22380 (1996-07-01), None
patent: WO 96/33735 (1996-10-01), None
patent: WO 96/34096 (1996-10-01), None
patent: WO 97/07671 (1997-03-01), None
patent: WO-97/13852 (1997-04-01), None
patent: WO-97/20574 (1997-06-01), None
patent: WO-97/38137 (1997-10-01), None
patent: WO 98/24884 (1998-06-01), None
patent: WO 98/24893 (1998-06-01), None
patent: WO 98/24893 (1998-06-01), None
patent: WO 98/37757 (1998-09-01), None
patent: WO 98/42752 (1998-10-01), None
patent: WO-98/46996 (1998-10-01), None
patent: WO-98/50433 (1998-11-01), None
patent: WO 00/10383 (2000-03-01), None
patent: WO-00/32231 (2000-06-01), None
patent: WO 00/37504 (2000-06-01), None
patent: WO 01/14424 (2001-03-01), None
Tivol et al., Immunity, 1995, 3: 541-547; reference provided by Applicant.
Blair et al., (1998) “Cutting Edge: CTLA-4 Ligation Delivers a Unique Signal to Resting Human CD4 T Cells That Inhibits Interleukin-2 Secretion but Allows Bcl-XLInduction”,J. of Immunology, 160:12-15.
J. Bluestone (1997) “Is CTLA-4 a Master Switch for Peripheral T Cell Tolerance?”,J. of Immunology, 158:1989-1993.
Brunet et al., (1988) “A Differential Molecular Biology Search for Genes Preferentially Expressed in Functional T Lymphocytes: The CTLA Genes”,Immunological Reviews, 103:21-36.
Brunet et al., (1987) “A new member of the immunoglubulin superfamily—CTLA-4”,Nature, 328:267-270.
Chambers and Allison (1997) “Co-stimulation in T cell responses”,Current Opinion in Immunology, 9:396-404.
Chambers et al., (1997) “Lymphoproliferation in CTLA-4-Deficient Mice Is Mediated by Costimulation-Dependent Activation of CD4+T Cells”,Immunity, 7:885-895.
Clark et al., (1986) “Polypeptides on Human B Lymphocytes Associated with Cell Activation”,Human Immunology, 16:100-113.
Damle et al., (1981) “Monoclonal antibody analysis of human T lymphocyte subpopulations exhibiting autologous mixed lymphocyte reaction”,Proc. Natl. Acad. Sci. USA, 78:5096-5098.
Dariavach et al., (1988) “Human Ig superfamily CTLA-4 gene: chromosomal localization and identity of protein sequence between murine and human CTLA-4 cytoplasmic domains”,Eur. J. Immunol., 18:1901-1905.
Fishwild et al., (1996) “High-avidity human IgGk monoclonal antibodies from a novel strain of minilocus transgenic mice”,Nature Biotechnology, 14:845-851.
Freedman et al., (1987) “B7, a B cell-restricted antigen that identifies preactivated B cells”,The J. of Immunology, 139:3260-3267.
Freeman et al., (1989) “B7, a new member of the Ig superfamily with unique expression on activated and neoplastic B cells”,The J. of Immunology, 143:2714-2722.
Gribben et al., (1995) “CTLA4 mediates antigen-specific apoptosis of human T cells”,Proc. Natl. Acad. Sci. USA, 92:811-815.
Hurwitz et al., (1998) “CTLA-4 blockade synergizes with tumor-derived granulocyte-macrophage colony-stimulating factor for treatment of an experimental mammary carcinoma”,Proc. Natl. Acad. Sci. USA, 95:10067-10071.
Hurwitz et al., (2000) “Immunotherapy of Primary Prostate Cancer in a Transgenic Model Using a Combination of CTLA-4 Blockade and Tumor Cell Vaccine”,Cancer Research, 60:2444-2448.
Kearney et al., (1995) “Antigen-Dependent Clonal Expansion of a Trace Population of Antigen-Specific CD4+T Cells In Vivo Is Dependent on CD28 Costimulation and Inhibited by CTLA-4”,The J. of Immunology, 155:1032-1036.
Kohno et al., (1990) “CD28 Molecule as a Receptor-like Function for Accessory Signals in Cell-Mediated Augmentation of IL-2 Production”,Cellular Immunology, 131:1-10.
Krummel and Allison (1995) “CD28 and CTLA-4 Have Opposing Effects on the Response of T cells to Stimulation”,J. Exp. Med., 182:459-464.
Krummel and Allison (1996) “CTLA-4 Engagement Inhibits IL-2 Accumulation and Cell Cycle Progression upon Activation of Resting T Cells&#x

Affiliated with

Also associated with

Rating

Methods of treatment using CTLA-4 antibodies does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Methods of treatment using CTLA-4 antibodies, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods of treatment using CTLA-4 antibodies will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4023330